In This Article:
Delivra Health Brands (CVE:DHB) Second Quarter 2025 Results
Key Financial Results
-
Revenue: CA$2.75m (up 34% from 2Q 2024).
-
Net loss: CA$812.0k (loss widened by 25% from 2Q 2024).
-
CA$0.026 loss per share (further deteriorated from CA$0.024 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Delivra Health Brands Earnings Insights
Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 8.0% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are up 26% from a week ago.
Risk Analysis
You should learn about the 3 warning signs we've spotted with Delivra Health Brands (including 2 which don't sit too well with us).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.